Pershing Edward 4

What Happened Pershing Edward, CEO and Director of Provectus Biopharmaceuticals (PVCT), was reported as the recipient of a derivative award on 2026-03-05. The Form 4 lists an acquisition-type entry (A) for a derivative instrument with "N/A" shares at $0.00 — no share count or dollar value for the award is provided on the form. The award relates to an 8% unsecured convertible promissory note issued in the Issuer's 2025 financing (see footnotes).

Key Details

• Transaction date: 2026-03-05; Form filed: 2026-03-06 (timely for a Form 4).
• Reported transaction: Grant/award of a derivative instrument; the Form shows N/A shares at $0.00 (no numeric share count or cash value reported).
• Footnote F1: The reporting person may elect to convert the outstanding principal & interest of the 8% convertible note into Series D‑1 Convertible Preferred Stock at $2.862 per Series D‑1 preferred share; automatic conversion occurs 12 months after the note issue date.
• Footnote F2: Each Series D‑1 preferred share converts into 10 shares of common stock; Series D‑1 preferred will automatically convert into common on 12/31/2028 unless converted earlier.
• Shares owned after transaction: Not specified on the Form 4.
• Filing status: Appears timely (no late-filing flag reported).

Context This filing documents a derivative award/convertible-note-related right rather than an open‑market buy or sale. If the note is converted into Series D‑1 preferred at $2.862 per preferred and each preferred converts into 10 common shares, the implied conversion price per common share would be $2.862 / 10 = $0.2862. Automatic and optional conversion features mean the timing and ultimate number of common shares that could result from this award depend on future conversion elections and the note’s automatic conversion provisions. This type of award indicates a financing/structural arrangement rather than an immediate cash purchase or sale of common stock.